It appears you're interested in "Gern stock," which most likely refers to Geron Corporation (GERN), a biopharmaceutical company listed on NasdaqGS. Geron focuses on developing therapeutic products for oncology, with its primary investigational compound, imetelstat, targeting hematologic myeloid malignancies.1
Here's a data-driven overview of GERN:
Recent Performance & Valuation
- As of August 6, 2025, GERN's share price was $1.39, marking a 26.36% increase from the prior week. However, the stock has experienced a significant decline of 69.78% over the past year.1
- The company has a market capitalization of $925.98 million.1
- Analyst sentiment suggests a potential upside, with an average one-year price target of $3.46, ranging from $1.01 to $6.30. This implies a projected increase of 148.68% from the August 6, 2025 price.2
Institutional Ownership & Sentiment
- Geron Corporation has substantial institutional interest, with 452 institutional owners holding a total of 576.28 million shares, representing 90.48% of the shares outstanding (excluding 13D/G filings).3
- Key institutional holders include Ra Capital Management, BlackRock, Inc., and Vanguard Group Inc..3
- While the total institutional shares held increased by 4.72% quarter-over-quarter, the number of institutional owners decreased by 7.19%.3 Fintel's Fund Sentiment Score, which measures institutional accumulation, is relatively low at 11.09 out of 100.4 This suggests that while some institutions are increasing their positions, the overall sentiment for new accumulation might be subdued or offset by other factors in the multi-factor model.
Short Interest
- Geron has notable short interest, with 67.96 million shares shorted as of August 6, 2025. The short interest as a percentage of float stands at 12.64%, and it would take approximately 5.30 days to cover these short positions.1
- Off-exchange short volume accounted for 63.89% of the total on August 6, 2025, indicating significant shorting activity outside traditional exchanges.5
Analyst Ratings & Fundamental Scores
- Analyst ratings for GERN are mixed but lean positive, with several "Buy" or "Sector Outperform" recommendations. However, there have been recent downgrades, such as Scotiabank's shift from "Sector Outperform" to "Sector Perform" in May 2025, and Goldman Sachs reiterated a "Sell" rating in July 2025.1
- Fintel's factor analysis indicates a Piotroski F-SCORE of 2.00 out of 9, suggesting a weak financial position.1
- The company scores 70.61/100 for Growth, but significantly lower for Profitability (8.27/100) and Quality (22.17/100).4
For a deeper dive, you can explore Geron Corporation's detailed institutional ownership data, short interest trends, and analyst forecasts directly on Fintel.
